搭建乙型肝炎临床治愈及预防母婴传播的临床研究协作网络平台

尹雪如; 侯金林

doi:10.3969/j.issn.1001-5256.2017.08.001

搭建乙型肝炎临床治愈及预防母婴传播的临床研究协作网络平台

DOI: 10.3969/j.issn.1001-5256.2017.08.001

南方医科大学南方医院感染内科暨肝病中心

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2363
- HTML全文浏览量: 39
- PDF下载量: 638
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-24
- 出版日期: 2017-08-20

Establishment of a clinical research collaborative network for clinical cure of hepatitis B and prevention of mother-to-child transmission

Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University

摘要

摘要: 慢性HBV感染是严重威胁全球人类健康的疾病之一。搭建国家、亚太地区以及全球不同层面的乙型肝炎临床研究协作网络平台,不论是在探索治疗新策略以及相关生物学标志物方面,还是在预防乙型肝炎母婴传播等领域都非常重要,相信借助该平台实现没有乙型肝炎的未来终会成为现实。
- 肝炎,乙型 /
- 疾病传播,垂直 /
- 综合预防 /
- 合作行为 /
- 述评
Abstract: Chronic hepatitis B virus infection is a great threat to public health around the world. National, Asian-Pacific, or global clinical research collaborative network plays an important role in exploring new therapeutic strategies and biological markers and preventing mother-to-child transmission of hepatitis B. We believe that such network may help to realize a future without hepatitis B.
- hepatitis B /
- disease transmission, vertical /
- eniversal precautions /
- cooperative behavior /
- editorial

HTML全文

参考文献(34)

[1]SCHWEITZER A, HORN J, MIKOLAJCZYK RT, et al.Estimations of worldwide prevalence of chronic hepatitis B virus infection:a systematic review of data published between 1965 and 2013[J].Lancet, 2015, 386 (10003) :1546-1555.

[2]LIANG X, BI S, YANG W, et al.Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination[J].Vaccine, 2009, 27 (47) :6550-6557.

[3]BRAHM J, CASTERA L, HOU J, et al.Joint Society statement for elimination of viral hepatitis[J].Ann Hepatol, 2017, 16 (1) :6-7.

[4]WHO.Global health sector strategy on viral hepatitis 2016-2021[J/OL].http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1

[5]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[6]BUSTER EH, FLINK HJ, CAKALOGLU Y, et al.Sustained HBe Ag and HBs Ag loss after long-term follow-up of HBe Agpositive patients treated with peginterferon alpha-2b[J].Gastroenterology, 2008, 135 (2) :459-467.

[7]MARCELLIN P, BONINO F, YURDAYDIN C, et al.Hepatitis B surface antigen levels:association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients[J].Hepatol Int, 2013, 7 (1) :88-97.

[8]CHANG TT, LAI CL, KEW YOON S, et al.Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B[J].Hepatology, 2010, 51 (2) :422-430.

[9]MARCELLIN P, GANE E, FLISIAK R, et al.Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance:8 year results from two phase 3 trials[J].Hepatology, 2014, 60:313a-314a.

[10]XIE Q, ZHOU H, BAI X, et al.A randomized, open-label clinical study of combined pegylated interferon alfa-2a (40KD) and entecavir treatment for hepatitis B“e”antigen-positive chronic hepatitis B[J].Clin Infect Dis, 2014, 59 (12) :1714-1723.

[11]NING Q, HAN M, SUN Y, et al.Switching from entecavir to Peg IFN alfa-2a in patients with HBe Ag-positive chronic hepatitis B:a randomised open-label trial (OSST trial) [J].J Hepatol, 2014, 61 (4) :777-784.

[12]HU P, DOU XG, JIANG JN, et al.Increased and sustained HBs Ag loss in HBe Ag positive CHB patients switched from NUC to PegIFN alfa-2a:a randomised open label trial (NEW SWITCH study) [C].67th Annual Meeting of the American Association for the Study of Liver Diseases.Boston MA, USA, 2016.

[13] SUN J, MA H, XIE Q, et al.Response-guided peginterferon therapy in patients with HBe Ag-positive chronic hepatitis B:a randomized controlled study[J].J Hepatol, 2016, 65 (4) :674-682.

[14]MARCELLIN P, AHN SH, MA X, et al.Combination of tenofovir disoproxil fumarate and peginterferonα-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B[J].Gastroenterology, 2016, 150 (1) :134-144.

[15]FAN R, SUN J, HOU J.Combination therapy with tenofovir and peginterferon may not be translated into current clinical practice[J].Gastroenterology, 2016, 150 (5) :1253-1254.

[16] European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol, 2017, 67 (2) :370-398.

[17] SARIN SK, KUMAR M, LAU GK, et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int, 2016, 10 (1) :1-98.

[18]TERRAULT NA, BZOWEJ NH, CHANG K M, et al.AASLD guidelines for treatment of chronic hepatitis B[J].Hepatology, 2016, 63 (1) :261-283.

[19]FAN R, SUN J, YUAN Q, et al.Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBe Ag seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos (t) ide analogues[J].Gut, 2016, 65 (2) :313-320.

[20]MA SW, HUANG X, LI YY, et al.High serum IL-21 levels after12 weeks of antiviral therapy predict HBe Ag seroconversion in chronic hepatitis B[J].J Hepatol, 2012, 56 (4) :775-781.

[21]JANSEN L, KOOTSTRA NA, van DORT KA, et al.Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos (t) ide analogues[J].J Infect Dis, 2016, 213 (2) :224-232.

[22]WANG J, SHEN T, HUANG X, et al.Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J].J Hepatol, 2016, 65 (4) :700-710.

[23]Chinese Journal of Hepatology, Journal of Clinical Hepatology, Chinese Hepatology.Potential clinical significance of serum HBV RNA virus-like particles[J].J Clin Hepatol, 2016, 32 (9) :1635-1636. (in Chinese) 中华肝脏病杂志, 临床肝胆病杂志, 《肝脏》杂志.HBV RNA病毒样颗粒的潜在临床意义[J].临床肝胆病杂志, 2016, 32 (9) :1635-1636.

[24]WEN WH, CHANG MH, ZHAO LL, et al.Mother-to-infant transmission of hepatitis B virus infection:significance of maternal viral load and strategies for intervention[J].J Hepatol, 2013, 59 (1) :24-30.

[25]VISVANATHAN K, DUSHEIKO G, GILES M, et al.Managing HBV in pregnancy.Prevention, prophylaxis, treatment and follow-up:position paper produced by Australian, UK and New Zealand key opinion leaders[J].Gut, 2016, 65 (2) :340-350.

[26]ZOU H, CHEN Y, DUAN Z, et al.Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBs Ag-positive mothers[J].J Viral Hepat, 2012, 19 (2) :e18-e25.

[27]HAN GR, JIANG HX, WANG CM, et al.Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy[J].J Viral Hepat, 2017, 24 (6) :514-521.

[28]ZHANG H, PAN CQ, PANG Q, et al.Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice[J].Hepatology, 2014, 60 (2) :468-476.

[29]XU WM, CUI YT, WANG L, et al.Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection:a multicentre, randomized, double-blind, placebo-controlled study[J].J Viral Hepat, 2009, 16 (2) :94-103.

[30]PAN CQ, HAN GR, JIANG HX, et al.Telbivudine prevents vertical transmission from HBe Ag-positive women with chronic hepatitis B[J].Clin Gastroenterol Hepatol, 2012, 10 (5) :520-526.

[31]HAN GR, CAO MK, ZHAO W, et al.A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J].J Hepatol, 2011, 55 (6) :1215-1221.

[32]PAN CQ, DUAN Z, DAI E, et al.Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J].N Engl J Med, 2016, 374 (24) :2324-2334.

[33]FAN R, YIN X, LIU Z, et al.A hepatitis B-free generation in China:from dream to reality[J].Lancet Infect Dis, 2016, 16 (10) :1103-1105.

[34]Chinese Foundation for Hepatitis Prevention and Control;Chinese Society of Infectious Disease, Chinese Medical Association;Chinese Society of Hepatology, Chinese Medical Association.Management algorithm for interrupting mother-to-child transmission of hepatitis B[J].J Clin Hepatol, 2017, 33 (7) :1214-1217. (in Chinese) 中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会.乙型肝炎母婴阻断临床管理流程[J].临床肝胆病杂志, 2017, 33 (7) :1214-1217.

施引文献

资源附件(0)

访问统计